{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:24:31Z","timestamp":1785417871700,"version":"3.56.0"},"reference-count":20,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Although progression\u2010free survival (PFS) is a commonly used surrogate end\u2010point for clinical trials of follicular lymphoma (FL), no analyses have evaluated the strength of surrogacy for PFS with overall survival (OS). A systematic review was performed and 20 studies (total participants, 10\u2009724) met final inclusion criteria. PFS was weakly associated with OS (correlation coefficient; 0.383, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The coefficient of determination was 0.15 (95% CI: 0.002\u20130.35) suggesting 15% of OS variance could be explained by changes in PFS. This challenges the role for PFS as a surrogate end\u2010point for clinical trials and drug approvals.<\/jats:p>","DOI":"10.1111\/bjh.19449","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T03:16:03Z","timestamp":1712200563000},"page":"2237-2241","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Progression\u2010free survival is a weakly predictive surrogate end\u2010point for overall survival in follicular lymphoma: A systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2305-6299","authenticated-orcid":false,"given":"Charles J.","family":"Milrod","sequence":"first","affiliation":[{"name":"Department of Hematology\/Oncology Brown University  Providence Rhode Island USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang Woo","family":"Kim","sequence":"additional","affiliation":[{"name":"Warren Alpert School of Medicine Brown University  Providence Rhode Island USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8715-3207","authenticated-orcid":false,"given":"Christina","family":"Raker","sequence":"additional","affiliation":[{"name":"Lifespan Biostatistics, Epidemiology, Research Design, and Informatics, Rhode Island Hospital  Providence Rhode Island USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0102-6491","authenticated-orcid":false,"given":"Thomas A.","family":"Ollila","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology Brown University  Providence Rhode Island USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6472-6658","authenticated-orcid":false,"given":"Adam J.","family":"Olszewski","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology Brown University  Providence Rhode Island USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3354-4499","authenticated-orcid":false,"given":"Ari","family":"Pelcovits","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology Brown University  Providence Rhode Island USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,4]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2508"},{"issue":"3","key":"e_1_2_13_3_1","first-page":"1110","article-title":"Comparison in low\u2010tumor\u2010burden follicular lymphomas between an initial no\u2010treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice P","year":"1997","journal-title":"Clin Oncol"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14110-4"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00340-z"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01048-6"},{"key":"e_1_2_13_7_1","first-page":"860","article-title":"R\u2010CHOP treatment for patients with advanced follicular lymphoma: over 15\u2010year follow\u2010up of JCOG0203","volume":"204","author":"Watanabe T","year":"2023","journal-title":"Br J Haematol"},{"key":"e_1_2_13_8_1","unstructured":"Table of surrogate endpoints that were the basis of drug approval or licensure.U. S. Food Drug Adm. FDA.2022."},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967784.58441.b3"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18568"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34221"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.06.006"},{"key":"e_1_2_13_13_1","unstructured":"Institute for Quality and Efficiency in Health Care [Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen] (IQWiG). Validity of surrogate endpoints in oncology: executive summary."},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.5853"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0407"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0559-9"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00838"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.8651"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010263"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01073"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.209015"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.19449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T10:09:02Z","timestamp":1754993342000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.19449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,4]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1111\/bjh.19449"],"URL":"https:\/\/doi.org\/10.1111\/bjh.19449","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,4]]},"assertion":[{"value":"2024-02-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}